Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients

Abstract

High mortality rates have been reported among antineutrophil cytoplasmic antibody-associated vasculitis (ANCA-AAV) patients with concomitant COVID-19 infection.1 Rituximab, an anti-CD20 monoclonal antibody, has been widely used for remission induction and maintenance in AAV. Despite advancements in vaccine strategies to provide protection against SARS-CoV-2, AAV patients on rituximab therapy remain vulnerable with poor humoral response to the SARS-CoV-2 vaccine.2 In light of these findings, monoclonal antibodies have been developed to provide passive immunity against SARS-CoV-2 in patients with depressed immune systems.

Topics & Concepts